These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25030485)

  • 1. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
    Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats.
    McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
    McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
    Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reepithelialization of the human cornea is regulated by endogenous opioids.
    Zagon IS; Sassani JW; McLaughlin PJ
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis.
    McLaughlin PJ; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2013 Jul; 238(7):733-43. PubMed ID: 23788174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the OGF-OGFr pathway in diabetic bone.
    Titunick MB; Lewis GS; Cain JD; Zagon IS; McLaughlin PJ
    Connect Tissue Res; 2019 Nov; 60(6):521-529. PubMed ID: 30931654
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
    Kren NP; Zagon IS; McLaughlin PJ
    Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
    Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ
    Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.
    Diaz D; Sassani JP; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2024; 249():10175. PubMed ID: 38756167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats.
    Purushothaman I; Zagon IS; Sassani JW; Mclaughlin PJ
    Exp Ther Med; 2021 Jul; 22(1):687. PubMed ID: 33986852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of opioid receptor blockade determines biotherapeutic response.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.